Trisodium hydrogen ethylenediaminetetraacetate

Endpoint summary

Key value for chemical safety assessment

Effects on fertility

Effect on fertility: via oral route

Endpoint conclusion:

no study available

Effect on fertility: via inhalation route

Endpoint conclusion:

no study available

Effect on fertility: via dermal route

Endpoint conclusion:

no study available

Effects on developmental toxicity

Description of key information

Developmental toxicity study (equivalent or similar to OECD 414), rats:

LOAEL maternal animals: 1245 mg/kg bw/day (highest dose tested)

NOAEL embryo-fetal development: >= 1245 mg/kg bw/day (highest dose tested)

NOAEL fetal abnormalities: >= 1245 mg/kg bw/day (highest dose tested)

Link to relevant study records

Reference

Endpoint:

developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 414 (Prenatal Developmental Toxicity Study)

Version / remarks:

study was conducted before guideline was adopted

Deviations:

yes

Remarks:

treatment from gestation day 7 to 14

Principles of method if other than guideline:

Edetic acid (EDTA) and four of its salts, disodium, trisodium, calcium di-sodium, and tetrasodium EDTA, were studied for teratogenic potential in rats. Equimolar doses based on 1000 mg/kg were given by gastric intubation on days 7 to 14 of gestation. On day 21 of gestation the dams of each group were sacrificed and litter data for each dam collected.

GLP compliance:

no

Limit test:

yes

Species:

rat

Strain:

other: CD albino

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Weight at study initiation: mean weight 241 g
- Diet: Purina Lab Chow ad libitum
- Water: tap water ad libitum

Route of administration:

oral: gavage

Vehicle:

other: 0.2 M phosphate buffer

Details on exposure:

- pH of dosing solution: 7.9

Analytical verification of doses or concentrations:

no

Details on mating procedure:

- Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Proof of pregnancy: vaginal plug, sperm in vaginal smear referred to as day 0 of pregnancy

Duration of treatment / exposure:

8 days (day 7 to day 14 of gestation)

Frequency of treatment:

daily, the total daily dose was equally divided into two daily doses

Duration of test:

21 days

Dose / conc.:

1 245 mg/kg bw/day (actual dose received)

Remarks:

divided into two equal daily doses

No. of animals per sex per dose:

20

Control animals:

yes, concurrent no treatment

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: Dose levels were chosen from preliminary studies with EDTA in which there was some evidence of both maternal and fetotoxicity at 1000 mg/kg bw/day.

Maternal examinations:

CAGE SIDE OBSERVATIONS: Yes

BODY WEIGHT: Yes
- Time schedule for examinations: once a week

FOOD CONSUMPTION: Yes

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21

Ovaries and uterine content:

The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes

Fetal examinations:

- External examinations: each fetus
- Gross inspection, slicing and visceral abnormalties: 1/3 of the litter
- Skeletal examinations: 2/3 of the litter

Statistics:

Means and standard errors were calculated for litter size, followed by analysis of variance. Pre- and postimplantation losses, embryonic viability, and fetal survival were evaluated by analysis of covariance. Fetal weights were also evaluated by analysis of covariance following calculation of mean weight/litter by sex, the values representing means and standard errors of mean litter weights. Significant variance by either analysis of variance or covariance was further evaluated by Dunnett's t test to locate the source of variance. Sex distribution was analyzed by partitioned a chi-squeared test.

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

Significant drug-related reactions included diarrhea and reduced activity. Diarrhea generally occurred daily following treatment and ultimately disappeared on the last day of dosing or the day after. The incidence of diarrhea was 35%. Transient episodes of reduced activity were seen on the first day of dosing in one dam.

Dermal irritation (if dermal study):

not examined

Mortality:

mortality observed, non-treatment-related

Description (incidence):

Two dams had to be sacrificed as a result of a dosing error (intubarion into the lungs).

Body weight and weight changes:

effects observed, treatment-related

Description (incidence and severity):

Treatment with the test item caused reduced body weight gain. Recovery was evident once treatment was terminated (see Table 1).

Food consumption and compound intake (if feeding study):

effects observed, treatment-related

Description (incidence and severity):

During treatment (gestation days 7-14) food intake was slihghtly decreased in the test item groups compared to the vehicle and untreated controls. During the post-treatment period (gestation days 14-21) food intake for the treated dams was similar to or slightly greater than that of dams in both control groups (see Table 1).

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

not examined

Clinical biochemistry findings:

not examined

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Immunological findings:

not examined

Organ weight findings including organ / body weight ratios:

not examined

Gross pathological findings:

not specified

Neuropathological findings:

not examined

Histopathological findings: non-neoplastic:

not examined

Histopathological findings: neoplastic:

not examined

Other effects:

not examined

Number of abortions:

no effects observed

Description (incidence and severity):

No abortions were noted.

Pre- and post-implantation loss:

no effects observed

Total litter losses by resorption:

no effects observed

Early or late resorptions:

no effects observed

Dead fetuses:

no effects observed

Changes in pregnancy duration:

no effects observed

Changes in number of pregnant:

no effects observed

Key result

Dose descriptor:

LOAEL

Remarks:

general maternal toxicity

Effect level:

1 245 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: diarrhea, slightly reduced food intake, slightly reduced body weight gain

Key result

Dose descriptor:

NOAEL

Remarks:

developmental toxicity

Effect level:

>= 1 245 mg/kg bw/day (actual dose received)

Based on:

test mat.

Basis for effect level:

other: no adverse developmental effects noted

Fetal body weight changes:

no effects observed

Description (incidence and severity):

Fetal body weights were similar to those of the two control groups (see Table 2).

Reduction in number of live offspring:

no effects observed

Description (incidence and severity):

Mean litter size and number of live fetuses per dam were similar to those in the two control groups (see Table 2).

Changes in sex ratio:

no effects observed

Description (incidence and severity):

The sex ratio was close to 50% in all groups (see Table 2).

Changes in litter size and weights:

not examined

Changes in postnatal survival:

not examined

External malformations:

effects observed, non-treatment-related

Description (incidence and severity):

A total of 1084 fetuses from EDTA and EDTA salt-treated dams were examined. These were compared to 237 fetuses from 19 dams treated with the vehicle and 278 fetuses from 20 untreated dams.
One untreated control fetus had multiple abnormalities including eye defect, ectrodactyly, and a curly tail.

Skeletal malformations:

effects observed, non-treatment-related

Description (incidence and severity):

Only summary data from all EDTA and EDTA salt--treated groups were reported. Of the 752 fetuses treated with EDTA or its salts and were skeletally examined 24 fetuses has skeletal abnormalities. These included 20 with bifid vertebra, 1 with agenesis of ribs, 2 with inhibition of osteogenesis of the shull or ribs and 1 with malformed ribs. There was no definitive pattern regarding treatment with a particular compound and the occurrence of anomalies.

None of the fetuses in the vehicle control group had abnormalities while 8 untreated control fetuses exhibited some major defect.
One untreated control fetus was stunted and had multiple abnormalities including ectrodactyly, and a curly tail. Five additional control fetuses had bifid vertebrae while 2 had malformed vertebrae or sternebrae.

Visceral malformations:

no effects observed

Description (incidence and severity):

On untreated control fetus had multiple abnormalities including eye defect. Histological examination of the eyes revealed a cataract in one eye and a dysmorphic lens and retina in the other.

Other effects:

not examined

Key result

Dose descriptor:

NOAEL

Effect level:

>= 1 245 mg/kg bw/day (actual dose received)

Basis for effect level:

other: no adverse treatment-related effects noted

Abnormalities:

no effects observed

Developmental effects observed:

no

Table 1: Food consumption and weight gain in rats treated with EDTA and EDTA salts on days 7 through 14 of gestation

Days	Control (untreated)	Vehicle Control	967 mg/kg bw/day EDTA	1243 mg/kg bw/day disodium EDTA	1245 mg/kg bw/day trisodium EDTA	1340 mg/kg bw/day calcium disodium EDTA	1374 mg/kg bw/day tetrasodium EDTA
	Mean food consumption (g/day)
0-7	20.7	21.4	19.9	20.4	19.9	20.4	19.0
7-14	22.3	22.5	18.4	17.5	19.1	20.9	18.5
14-21	24.7	25.3	26.7	27.2	25.7	26.5	25.6
	Mean body weight gain (g)
0-7	31.9	35.1	37.6	35.6	33.2	37.2	26.9
7-14	28.5	26.1	16.5	13.7	20.4	25.1	18.3
14-21	102.7	93.3	104.4	100.2	98.4	108.1	94.2

Table 2: Reproductive data in dams receiving EDTA and EDTA salts on days 7 through 14 of gestation

				Fetuses
				Sex		Body weight (mean g ± SE)		Number
Treatment	No of dams	Litter size (mean ± SE)	Post implantation loss (%)	M	F	M	F	Dead	Live	Resorbed
Control (untreated)	20	14.0 ± 0.4	4	52	48	5.3 ± 0.1	5.6 ± 0.1	1	278	12
Vehicle Control	19	12.5 ± 0.1	3	50	50	5.3 ± 0.1	5.7 ± 0.1	0	237	7
967 mg/kg bw/day EDTA	17	12.7 ± 0.6	3	49	51	5.5 ± 0.1	5.7 ± 0.1	0	216	6
1243 mg/kg bw/day Na2 EDTA	19	12.6 ± 0.4	1	56	44	5.4 ± 0.1	5.6 ± 0.1	0	202	3
1245 mg/kg bw/day Na3 EDTA	18*	12.4 ± 1.0	8	48	52	5.4 ± 0.2	5.7 ± 0.1	0	210	11
1340 mg/kg bw/day CaNa2 EDTA	17	13.5 ± 0.4	2	52	48	5.3 ± 0.1	5.6 ± 0.1	0	230	4
1374 mg/kg bw/day Na4 EDTA	19	11.9 ± 0.7	4	47	52	5.2 ± 0.1	5.5 ± 0.1	0	226	10

* 2 dams had to be killed due to dosing errors

Conclusions:

No test item-related effects on embryo-fetal development could be detected in the study. Under the conditions of the test the NOAEL for maternal and embryo-featl developmental toxicity in rats is >= 1245 mg/kg bw/day.

Effect on developmental toxicity: via oral route

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

1 245 mg/kg bw/day

Study duration:

subacute

Species:

rat

Quality of whole database:

The available information comprises an adequate and reliable study (Klimisch score 2), and are thus sufficient to fulfil the standard information requirements set out in Annex VIII, 8.7, of Regulation (EC) No 1907/2006.

Effect on developmental toxicity: via inhalation route

Endpoint conclusion:

no study available

Effect on developmental toxicity: via dermal route

Endpoint conclusion:

no study available

Additional information

Trisodium hydrogen EDTA (CAS 150-38-9), EDTA and three further EDTA salts were evaluated for their teratogenic potential in CD albino rats (Schardein et al., 1981). Groups of 20 females were treated by gavage on gestation days 7-14 with 1000 mg EDTA/kg bw/day as well as with equimolar doses of disodium, trisodium, calcium disodium and tetrasodium edetate (dissolved and suspended in phosphate buffer). Trisodium EDTA was administered at a daily dose of 1245 mg/kg bw/day, equally divided into two daily doses. For the dams drug-related reactions including diarrhea (36% of animals affected) and reduced activity (one animals affected on treatment day 1) were reported. Two dams had to be killed due to an intubation error. Besides slightly decreased food intake, treatment with trisodium hydrogen EDTA caused reduced weight gain in the dams during the treatment period. The incidence of postimplantation loss, number of live and dead fetuses per dam, fetal weights and fetal sex ratios in the trisodium hydrogen EDTA group were similar to that of the vehicle and untreated control group. Fetuses were examined for external, visceral and skeletal anomalies. Incidental findings of skeletal anomalies did not reveal a definitive pattern regarding treatment with a particular compound. The authors stated that under these experimental conditions no teratogenic effects were evidenced even at maternally toxic doses. A maternal LOAEL was established at 1245 mg/kg bw/day, NOAELs for developmental toxicity and embryofetal development were established at 1245 mg/kg bw/day.

Toxicity to reproduction: other studies

Additional information

EDTA and four of its salts were evaluated for their teratogenic potential in CD albino rats (Schardein et al., 1981). Groups of 20 females were treated by gavage during gestation days 7-14 with 1000 mg EDTA/kg bw/day as well as with equimolar doses of disodium, trisodium (corresponding to 1245 trisodium EDTA mg/kg bw/day), calcium disodium and tetrasodium edetate (dissolved and suspended in phosphate buffer with final pH values ranging from 3.9 to 9.2). For the dams treated with trisodium EDTA, drug-related reactions including diarrhea and depression of activity were reported. The incidence of diarrhea was 35%. Transient episodes of reduced activity were seen on the first day of dosing in one dam. No test item-related mortality was noted for trisodium EDTA. Besides slightly decreased food intake, treatment caused reduced weight gain in the dams during the treatment period. The mortality index of offspring as measured by postimplantation loss was comparable to that of the vehicle and untreated control group. No effects on litter size at term or mean fetal body weight were noted. Fetuses were examined for external, visceral and skeletal anomalies. Incidental findings of skeletal anomalies did not reveal a definitive pattern regarding treatment. The authors stated that under these experimental conditions no teratogenic effects were evidenced even at maternally toxic doses.

Justification for classification or non-classification

The available data on toxicity to reproduction for trisodium hydrogen EDTA (CAS 150-38-9) do not indicate adverse effects up to and including the highest dose tested. Therefore, the available data are conclusive but not sufficient for classification according to Regulation (EC) No 1272/2008.